The company depends on specialty raw materials for gene-modified cell therapy manufacturing, many of which are supplied by small vendors with limited capacity to support commercial biopharmaceutical production under cGMP standards. Some raw materials are obtained from single or few suppliers, presenting risks if these suppliers cease operations or are acquired by competitors. The company does not have commercial supply agreements with many suppliers, which may result in delays in acquiring key raw materials. The company may pursue strategic alliances, joint ventures, collaborations, or licensing arrangements to support development and commercialization; however, these processes are complex, time-consuming, and may not succeed or deliver anticipated benefits. Delays in forming strategic partnerships could affect product development and commercialization timelines. The company has not previously submitted a Biologics License Application (BLA) or New Drug Application (NDA) to the FDA.
Anixa Biosciences Inc's Comment on Supply Chain
The company depends on specialty raw materials for gene-modified cell therapy manufacturing, many of which are supplied by small vendors with limited capacity to support commercial biopharmaceutical production under cGMP standards. Some raw materials are obtained from single or few suppliers, presenting risks if these suppliers cease operations or are acquired by competitors. The company does not have commercial supply agreements with many suppliers, which may result in delays in acquiring key raw materials. The company may pursue strategic alliances, joint ventures, collaborations, or licensing arrangements to support development and commercialization; however, these processes are complex, time-consuming, and may not succeed or deliver anticipated benefits. Delays in forming strategic partnerships could affect product development and commercialization timelines. The company has not previously submitted a Biologics License Application (BLA) or New Drug Application (NDA) to the FDA.
Sources:
Anixa Biosciences Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Anixa Biosciences Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
